Zobrazeno 1 - 10
of 1 114
pro vyhledávání: ''
Autor:
Diana Abbott, Clayton A. Smith, Julie Rosser, Mohd Minhajuddin, Maria L. Amaya, Jeffrey Schowinsky, Daniel A. Pollyea, Anagha Inguva, Craig T. Jordan, Amanda Winters, Christine McMahon, Jonathan A. Gutman, Audrey Sato, Evan Cherry, Marc Schwartz, Shanshan Pei, Brett M. Stevens
Publikováno v:
Blood Advances
Key Points Patients with AML who received IC were compared with those who received ven to investigate predictors of outcomes.Presence of RUNX1 mutations is associated with better outcomes for ven/aza compared with IC.
Visual Abstract
Veneto
Visual Abstract
Veneto
Autor:
Denise M. Wolf, Jane Perlmutter, Judy C. Boughey, A. Jo Chien, Meredith Buxton, Gillian L. Hirst, Douglas Yee, Angela DeMichele, Andres Forero-Torres, Scott M. Berry, Erin D. Ellis, Anthony D. Elias, Julia Wulfkuhle, Michael Alvarado, Christina Yau, Stacy L. Moulder, Nola M. Hylton, Rita Nanda, Amy Wilson, Adam Asare, Debu Tripathy, Claudine Isaacs, Melissa Paoloni, Rosa I. Gallagher, Laura J. Esserman, Richard Schwab, W. Fraser Symmans, Cheryl Ewing, Laura J. van't Veer, Jeffrey B. Matthews, Teresa Helsten, Julia L. Clennell, Barbara Haley, Emanuel F. Petricoin, Katherine Steeg, Smita Asare, Ashish Sanil, Rachel L. Yung, Erin P. Crane, Erin Roesch, Hyo S. Han, Ruby Singhrao, Michelle E. Melisko, Hope S. Rugo, Kathy S. Albain, Donald A. Berry, Anne M. Wallace, Julie E. Lang, Amy S. Clark, Kathleen Kemmer, Lamorna Brown-Swigart
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
Nature communications, vol 12, iss 1
Nature Communications
Nature communications, vol 12, iss 1
Nature Communications
HER2-targeted therapy dramatically improves outcomes in early breast cancer. Here we report the results of two HER2-targeted combinations in the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence: ad
Autor:
Nancy Chan, Jiuping Ji, Antoinette R. Tan, Janice M. Mehnert, Alice P. Chen, Jan H. Beumer, Mansi Shah, Joseph Aisner, Murugesan Gounder, Jyoti Malhotra, Rebecca A. Moss, Yong Lin, Brian F. Kiesel, Hongxia Lin, Mark N. Stein, Michael P. Kane
Publikováno v:
Cancer Chemother Pharmacol
Purpose Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus
Autor:
Mohammad Ghasemi, Andrew Goey, John Wilton, Wiam Bshara, Adrienne Groman, Renuka Iyer, Christos Fountzilas, Wen Wee Ma, Mateusz Opyrchal, Alex A. Adjei, Rachel Evans, Kristopher Attwood
Publikováno v:
Int J Cancer
In this phase I, dose-escalation study, we sought to determine the maximum tolerated dose (MTD) of the anaplastic lymphoma kinase/c-ROS oncogene 1 receptor (ALK/ROS1) inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients
Autor:
Silvia Olivari, Gary Binder, Erminio Bonizzoni, Eric Roeland, Rudolph M. Navari, Rebecca Clark-Snow
Publikováno v:
Future Oncology. 17:3027-3035
Aim: In the absence of comparative studies, guidelines consider neurokinin 1 receptor antagonists (RAs) as interchangeable. We evaluated the pooled efficacy from three cisplatin registration trials, each with arms containing netupitant/palonosetron (
Autor:
Sophie Alberdine Kurk, Bart A. W. Jacobs, Jacob Hendrik Beijnen, Neeltje Steeghs, Thomas P.C. Dorlo, Laura Molenaar-Kuijsten, Anne Maria May, Alwin Dagmar Redmar Huitema
Publikováno v:
Cancer medicine, 10(14), 4781-4789. John Wiley and Sons Ltd
Cancer Medicine
Cancer Medicine, Vol 10, Iss 14, Pp 4781-4789 (2021)
Cancer Medicine
Cancer Medicine, Vol 10, Iss 14, Pp 4781-4789 (2021)
Background A low skeletal muscle mass (SMM) has been associated with increased toxicity and shorter survival in cancer patients treated with capecitabine, an oral prodrug of 5‐fluorouracil (5‐FU). Capecitabine and its metabolites are highly water
Publikováno v:
Current Medical Science. 41:491-497
All-trans retinoic acid (ATRA) and pre-upfront arsenic trioxide (ATO) have revolutionized the therapy of acute promyelocytic leukemia (APL). However, internal tandem duplication of FMS-like tyrosine kinase 3 (FLT3-ITD) mutations is associated with in
Autor:
Saja B Alzughoul, Hala T Abu Kassab, Ayat J Abu Shameh, Mohammad K Alhazabreh, Sana'a A Jaber, Amani D Abu Kwiak, Salam S Abu Laila, Mays M Jaradat, Nour M Al-Daoud, Mo'tasem M Alsmadi
Publikováno v:
Biopharmaceutics & Drug Disposition. 42:263-284
Renal (RIP) and hepatic (HIP) impairments are prevalent conditions in cancer patients. They can cause changes in gastric emptying time, albumin levels, hematocrit, glomerular filtration rate, hepatic functional volume, blood flow rates, and metabolic
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Cancer
BMC Cancer
Background Regorafenib has shown promising results as a second-line therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib. Although there have been several data regarding the efficacy of sequential therapy with sorafeni
Autor:
Sapna Pradyuman Patel, David S. Hong, Vivek Subbiah, Amanda Johnston, Siqing Fu, John S. Bomalaski, Sarina Anne Piha-Paul, Shuyang Yao, Ahmed Kaseb, Aung Naing, Nai Shi, Filip Janku, Apostolia Maria Tsimberidou, Shannon N. Westin, John Stewart
Publikováno v:
Br J Cancer
Background Arginine depletion interferes with pyrimidine metabolism and DNA damage-repair pathways, and pairing arginine deiminase pegylated with 20,000-molecular-weight polyethylene glycol (ADI-PEG20) with platinum enhances cytotoxicity in vitro and